ionscope bags investment for microscope development:
This article was originally published in Clinica
London, UK-based ionscope has raised £680,000 ($1.4m) from technology investors Cambridge Angels Group. Ionscope plans to use the funds to further development of its line of products based around a technique called scanning ion conductance microscopy (SICM), which the company claims produces images of living cell membranes at resolutions 50 times greater than conventional microscopes. SICM is a benign procedure, which means it does not kill living cells.
You may also be interested in...
Perrigo, Pfizer want the US FDA to postpone its March 1 deadline for conducting nitrosamine risk assessments. Generics exec cites“serious compliance challenges” in conducting these assessments due to difficulty in finding the right lab equipment necessary to quantify nitrosamine daily intake limits.
Deal snapshot: For $425m up front, the pharma obtains a Phase III recombination fusion protein that shows ability to improve hospitalized patients’ clinical status and reduce risk of death.
Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.